cpped1 Antibody

What is CPPED1 and why is it significant in metabolic research?

CPPED1 is a novel molecule expressed in adipose tissue (AT) that plays an inhibitory role in glucose uptake by adipocytes. Its significance lies in its involvement in glucose metabolism, particularly in the context of obesity and type 2 diabetes. Research has demonstrated that CPPED1 expression decreases in subcutaneous adipose tissue after weight reduction, suggesting its potential role in metabolic dysfunction associated with obesity . Understanding CPPED1 function is valuable for researchers investigating metabolic disorders, as knockdown of CPPED1 expression enhances insulin-stimulated glucose uptake in mature adipocytes, possibly through adiponectin-mediated mechanisms .

What are the typical applications for CPPED1 antibodies in research?

CPPED1 antibodies are versatile tools in research with several validated applications:

These antibodies typically show reactivity with human and mouse samples, making them suitable for comparative studies between models . The recommended dilutions vary by application, with Western blotting typically using 1:200-1:1000 and immunohistochemistry requiring 1:20-1:200 .

How does knockdown of CPPED1 affect glucose metabolism in adipocytes?

Knockdown of CPPED1 using small interfering RNA (siRNA) in mature adipocytes produces several significant metabolic effects:

• Increased insulin-stimulated glucose uptake (+74% compared to control cells)

• Upregulation of genes involved in glucose metabolism:

  • Adiponectin (ADIPOQ)

  • Adiponectin receptor 1

  • GLUT4 (glucose transporter 4)

• Decreased expression of GLUT1 and leptin (LEP)

• Increased adiponectin protein expression (+32% at 96h post-treatment)

• Enhanced high-molecular-weight (HMW) adiponectin secretion

These effects appear to be mediated through a phosphatidylinositol 3-kinase (PI3K)/Akt-dependent pathway, as wortmannin (a PI3K inhibitor) abolishes the CPPED1 knockdown-induced improvement in glucose uptake . This suggests that CPPED1 may represent a potential therapeutic target for improving insulin sensitivity in metabolic disorders.

What are the considerations for validating specificity when using CPPED1 antibodies?

Validating antibody specificity is crucial for reliable CPPED1 research. Consider these approaches:

• Positive and negative controls: Use recombinant CPPED1 protein as a positive control . For negative controls, consider CPPED1 knockout models or siRNA-treated samples with confirmed CPPED1 downregulation.

• Multiple detection methods: Validate findings using different techniques (e.g., WB, IHC, and ICC) to confirm consistency in CPPED1 detection .

• Blocking peptide experiments: Pre-incubate the antibody with the immunizing peptide to demonstrate signal specificity.

• Molecular weight verification: Confirm that the detected band corresponds to the expected molecular weight (28-35 kDa for most isoforms) .

• Cross-reactivity assessment: If working with multiple species, verify specificity in each species of interest, as antibody performance may vary despite predicted cross-reactivity.

What are the optimal protocols for using CPPED1 antibodies in Western blotting?

For optimal Western blot results with CPPED1 antibodies:

• Sample preparation:

  • Use RIPA buffer supplemented with protease inhibitors

  • Load 20-50 μg of total protein per lane

  • Denature samples at 95°C for 5 minutes in reducing sample buffer

• Electrophoresis and transfer:

  • Use 10-12% SDS-PAGE gels for optimal separation

  • Transfer to PVDF membranes at 100V for 60-90 minutes

• Antibody incubation:

  • Block membranes with 5% non-fat milk or BSA in TBST

  • Dilute primary CPPED1 antibody 1:200-1:1000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Use appropriate HRP-conjugated secondary antibody (typically 1:5000-1:10000)

• Detection:

  • Use enhanced chemiluminescence (ECL) for visualization

  • For quality control, 5μL per well is recommended when using ECL

• Expected results:

  • Look for bands at 28-35 kDa (main isoforms) and potentially at ~20 kDa (alternative isoforms)

  • Positive control: Recombinant CPPED1 or SMMC-7721 cells

What immunohistochemistry protocols are recommended for CPPED1 detection in tissue samples?

For effective IHC detection of CPPED1:

• Tissue preparation:

  • Use formalin-fixed, paraffin-embedded (FFPE) or frozen sections

  • For FFPE sections, 4-6 μm thickness is optimal

• Antigen retrieval:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Heat-induced epitope retrieval (pressure cooker or microwave)

• Antibody incubation:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with serum or protein block

  • Dilute CPPED1 antibody 1:20-1:200 in antibody diluent

  • Incubate overnight at 4°C or 1-2 hours at room temperature

• Detection system:

  • Use polymer-based detection systems for enhanced sensitivity

  • For DAB staining, 10μL per well is recommended for visualization

  • Counterstain with hematoxylin for nuclear visualization

• Validated tissues:

  • Human liver cancer tissue has shown positive results

  • Adipose tissue is relevant for metabolic studies

What are the storage and handling recommendations for maintaining CPPED1 antibody activity?

To preserve antibody activity and functionality:

• Storage conditions:

  • Store at -20°C for long-term storage

  • For antibodies in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3), aliquoting is unnecessary for -20°C storage

  • Avoid repeated freeze-thaw cycles that can degrade antibody quality

• Working solution handling:

  • Store at 4°C for frequent use (short-term)

  • Prepare fresh dilutions for each experiment when possible

  • Return stock solution to -20°C promptly after use

• Stability:

  • Properly stored antibodies typically remain stable for one year after shipment

  • Small-volume aliquots (20μL) containing 0.1% BSA may have enhanced stability

• Safety considerations:

  • Follow standard laboratory safety procedures when handling antibodies

  • Note that some formulations contain sodium azide (0.02%), which is toxic and should be handled accordingly

How can researchers troubleshoot weak or absent CPPED1 signal in Western blots?

When facing detection challenges with CPPED1 antibodies:

• Sample issues:

  • Confirm CPPED1 expression in your sample type (SMMC-7721 cells are positive controls)

  • Increase protein loading (up to 50-75 μg)

  • Add protease inhibitors to prevent degradation during sample preparation

• Antibody optimization:

  • Try a range of antibody dilutions (starting with more concentrated 1:200)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use more sensitive detection systems (e.g., SuperSignal West Femto)

• Transfer efficiency:

  • Verify transfer efficiency with reversible staining (Ponceau S)

  • Optimize transfer conditions for proteins in the 28-35 kDa range

  • Consider semi-dry transfer for more efficient transfer of medium-sized proteins

• Blocking conditions:

  • Test alternative blocking agents (BSA vs. non-fat milk)

  • Reduce blocking time if over-blocking is suspected

• Positive controls:

  • Include recombinant CPPED1 as a positive control to verify antibody functionality

  • Consider using lysates from cells with confirmed CPPED1 expression

What approaches can be used to study CPPED1 function in relation to glucose metabolism?

To investigate CPPED1's role in glucose metabolism:

• Knockdown studies:

  • Use siRNA targeting CPPED1 (validated sequences: AGAAAAUUGUUCACCGAUA, UAAAUGCACUAAUGCGAAA, CGGAGGACCUGAAGCGAGU, and CCUUUAAAAUGGAGCGAAU)

  • Transfect using appropriate reagents like HiPerFect transfection reagent

  • Verify knockdown efficiency by RT-qPCR and Western blot

• Glucose uptake assays:

  • Measure basal and insulin-stimulated glucose uptake in control and CPPED1-modulated cells

  • Use radiolabeled glucose (e.g., 2-deoxy-D-[1,2-³H]-glucose) for quantification

  • Include wortmannin treatment to assess PI3K-dependency

• Gene expression analysis:

  • Monitor changes in glucose metabolism genes (ADIPOQ, adiponectin receptor 1, GLUT4, GLUT1)

  • Use RT-qPCR for mRNA quantification

  • Validate protein changes by Western blot

• Secretion assays:

  • Measure adiponectin (particularly HMW adiponectin) secretion using ELISA

  • Collect conditioned medium 48-96 hours after CPPED1 modulation

• Pathway analysis:

  • Investigate PI3K/Akt pathway components through phosphorylation status

  • Examine insulin signaling cascade elements in relation to CPPED1 expression

How can researchers validate antibody specificity in CPPED1 overexpression and knockdown models?

For rigorous validation of CPPED1 antibodies:

• Overexpression models:

  • Express tagged CPPED1 (e.g., His-tag, FLAG-tag) in cell lines

  • Confirm expression using tag-specific antibodies

  • Compare detection patterns between tag antibodies and CPPED1 antibodies

  • Verify signal increase proportional to expression levels

• Knockdown validation:

  • Implement siRNA knockdown (targeting sequences provided above)

  • Confirm mRNA reduction via RT-qPCR

  • Demonstrate corresponding protein reduction via Western blot

  • Show signal reduction in IHC/ICC of knockdown cells

• Quantitative assessment:

  • Perform densitometry on Western blots to quantify signal changes

  • Correlate protein levels with mRNA expression

  • Document temporal changes following knockdown/overexpression

• Multiple antibody validation:

  • Compare results using different antibodies targeting distinct CPPED1 epitopes

  • Use monoclonal and polyclonal antibodies to confirm specificity

  • Evaluate consistency of detection patterns across antibodies

• Functional correlation:

  • Link antibody detection with functional readouts (e.g., glucose uptake)

  • Confirm that protein level changes detected by the antibody correlate with expected functional changes